Iovance Biotherapeutics, Inc. · NASDAQ:IOVA

Iovance Biotherapeutics — Technical Presentation (March 2025)

9 slides from Iovance Biotherapeutics's technical presentation, March 2025

  1. Slide 1: Molecular Quantification and Tumor Reactivity Assessment of Tumor-infiltrating Lymphocytes Using Multiplexed Digital PCR

    Molecular Quantification and Tumor Reactivity Assessment of Tumor-infiltrating Lymphocytes Using Multiplexed Digital PCR Fadi El Rami, Joe Yglesias, Kranthi Kunkalla, Joe Dean, Hequn Yin, Brian Gastman, Peter A Prieto, Rongsu Qi Iovance Biotherapeutics, San Carlos, CA #SSO2O25 | SSO2O25.ORG

  2. Slide 2: Disclosures

    Disclosures FER, JY, KK, JD, HY, BG, PP, and RQ are employed by and own stock in Iovance Biotherapeutics. #SSO2O25 | SSO2O25.ORG

  3. Slide 3: Surgical oncologists play a very important role in tumor sample procurement

    Surgical oncologists play a very important role in tumor sample procurement 1 2 3 4 5 6 PATIENT TUMOR SAMPLE NMA-LD LIFILEUCEL IL-2 RECOVERY/ INTAKE PROCUREMENT INFUSION INFUSIONS DISCHARGE IL-2, interleukin-2; NMA-LD, nonmyeloablative lymphodepletion; TIL, tumor-infiltrating lymphocyte.

  4. Slide 4: Tumor quality is crucial for successful TIL manufacturing and efficacy

    Tumor quality is crucial for successful TIL manufacturing and efficacy Case 1: Melanoma Patient, Progressive Disease Case 2: Melanoma Patient, Partial Response • Low T-cell infiltration • Good T-cell infiltration – 4.17 g tumor digested – 1.68 g tumor digested – Minimal number of T cells retained –

  5. Slide 5: How can we detect region(s) with the most TIL infiltration from surgically resected tumors?

    How can we detect region(s) with the most TIL infiltration from surgically resected tumors?

  6. Slide 6: dPCR can discern tumor heterogeneity

    dPCR can discern tumor heterogeneity Interpatient heterogeneity Intratumor heterogeneity (% T cells in 77 clinical tumors) (% T cells in fragments dissected from same tumor) 100 50 90 40 80 70 30 60 T cell, % TIL, % 50 20 40 10 30 20 0 10 0 –10 Tumor FFPE 1 2 3 4 5 6 7 8 9 10 MRC5 (n=77) Tumor Fragm

  7. Slide 7: Can dPCR assess reactivity of tumor fragments?

    Can dPCR assess reactivity of tumor fragments? Tumor-reactivity profiling of tumor fragments dissected from the same tumor sample using dPCR TRBC CD200 CXCL13 1.5 Normalized Expression of Genes 1.0 0.5 0.0 1 2 3 4 5 7 8 9 10 Fragment dPCR, digital polymerase chain reaction; TRBC, T-cell receptor bet

  8. Slide 8: Conclusions

    Conclusions  Surgical oncologists play an essential role in tumor tissue procurement  Qualitative features of tumor tissue procurement are essential for optimized manufacturing and clinical success  Digital PCR provides an accurate and time-efficient tool to quantify TIL infiltration and its pote

  9. Slide 9: Thank You

    Thank You

Iovance Biotherapeutics — Technical Presentation (March 2025) on 6ix